Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo

Atherosclerosis

Volumn 189, Issue 2, 2006, Pages 408-413

  Niessner, Alexander ^a,b   Steiner, Sabine ^a   Speidl, Walter S ^a   Pleiner, Johannes ^a   Seidinger, Daniela ^a   Maurer, Gerald ^a   Goronzy, Jörg J ^b   Weyand, Cornelia M ^b   Kopp, Christoph W ^a   Huber, Kurt ^c   Wolzt, Michael ^a   Wojta, Johann ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b EMORY UNIVERSITY   (United States)

^c Cardiology and Emergency Medicine   (Austria)

Author keywords

Innate immune system; Lipopolysaccharides; Statins; Toll like receptor

Indexed keywords

ENDOTOXIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; SIMVASTATIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD ANALYSIS; CELL SURFACE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FLOW CYTOMETRY; HUMAN; IN VIVO STUDY; MALE; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTOXEMIA; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INJECTIONS, INTRAVENOUS; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; MALE; MONOCYTES; POLYMERASE CHAIN REACTION; REFERENCE VALUES; RNA, MESSENGER; SIMVASTATIN; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; UP-REGULATION;

EID: 33750360916     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.12.022     Document Type: Article

References (36)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-9.
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22.
3. Almog Y., Shefer A., Novack V., et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110 7 (2004) 880-885
4. Liappis A.P., Kan V.L., Rochester C.G., and Simon G.L. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33 8 (2001) 1352-1357
5. Ascer E., Bertolami M.C., Venturinelli M.L., et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177 1 (2004) 161-166
6. Pleiner J., Schaller G., Mittermayer F., et al. Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 110 21 (2004) 3349-3354
7. Martin-Ventura J.L., Blanco-Colio L.M., Gomez-Hernandez A., et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 36 8 (2005) 1796-1800
8. Pahan K., Sheikh F.G., Namboodiri A.M., and Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 100 11 (1997) 2671-2679
9. Steiner S., Speidl W.S., Pleiner J., et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111 14 (2005) 1841-1846
10. Akira S., Takeda K., and Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2 8 (2001) 675-680
11. Ashida K., Miyazaki K., Takayama E., et al. Characterization of the expression of TLR2 (toll-like receptor 2) and TLR4 on circulating monocytes in coronary artery disease. J Atheroscler Thromb 12 1 (2005) 53-60
12. Methe H., Kim J.O., Kofler S., Weis M., Nabauer M., and Koglin J. Expansion of circulating toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 111 20 (2005) 2654-2661
13. Xu X.H., Shah P.K., Faure E., et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 104 25 (2001) 3103-3108
14. Edfeldt K., Swedenborg J., Hansson G.K., and Yan Z.Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105 10 (2002) 1158-1161
15. Kiechl S., Lorenz E., Reindl M., et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347 3 (2002) 185-192
16. Boekholdt S.M., Agema W.R., Peters R.J., et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 107 19 (2003) 2416-2421
17. Fan J., Frey R.S., and Malik A.B. TLR4 signaling induces TLR2 expression in endothelial cells via neutrophil NADPH oxidase. J Clin Invest 112 8 (2003) 1234-1343
18. Faure E., Thomas L., Xu H., Medvedev A., Equils O., and Arditi M. Bacterial lipopolysaccharide and IFN-gamma induce toll-like receptor 2 and toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol 166 3 (2001) 2018-2024
19. Wiedermann C.J., Kiechl S., Dunzendorfer S., et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol 34 7 (1999) 1975-1981
20. Ohashi K., Burkart V., Flohe S., and Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 164 2 (2000) 558-561
21. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21 11 (2001) 1712-1719
22. Kadowaki N., Ho S., Antonenko S., et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194 6 (2001) 863-870
23. Jilma B., Blann A., Pernerstorfer T., et al. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med 159 3 (1999) 857-863
24. Wittebole X., Coyle S.M., Kumar A., Goshima M., Lowry S.F., and Calvano S.E. Expression of tumour necrosis factor receptor and toll-like receptor 2 and 4 on peripheral blood leucocytes of human volunteers after endotoxin challenge: a comparison of flow cytometric light scatter and immunofluorescence gating. Clin Exp Immunol 141 1 (2005) 99-106
25. Mirlashari M.R., and Lyberg T. Expression and involvement of toll-like receptors (TLR)2, TLR4, and CD14 in monocyte TNF-alpha production induced by lipopolysaccharides from Neisseria meningitidis. Med Sci Monit 9 8 (2003) BR316-BR324
26. Meier A., Kirschning C.J., Nikolaus T., Wagner H., Heesemann J., and Ebel F. Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillus-induced activation of murine macrophages. Cell Microbiol 5 8 (2003) 561-570
27. Branen L., Hovgaard L., Nitulescu M., Bengtsson E., Nilsson J., and Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 24 11 (2004) 2137-2142
28. Yla-Herttuala S., Lipton B.A., Rosenfeld M.E., et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 88 12 (1991) 5252-5256
29. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., and Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 7 (2001) 926-933
30. Methe H., Kim J.O., Kofler S., Nabauer M., and Weis M. Statins decrease toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol 25 7 (2005) 1439-1445
31. Kirsch C., Eckert G.P., and Mueller W.E. Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem Pharmacol 65 5 (2003) 843-856
32. Goebel J., Logan B., Forrest K., Mieczkowski A., Roszman T.L., and Wills-Karp M. Atorvastatin affects interleukin-2 signaling by altering the lipid raft enrichment of the interleukin-2 receptor Beta chain. J Investig Med 53 6 (2005) 322-328
33. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 10 (2004) 987-995
34. Muzio M., Bosisio D., Polentarutti N., et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 164 11 (2000) 5998-6004
35. Sabroe I., Jones E.C., Usher L.R., Whyte M.K., and Dower S.K. Toll-like receptor (TLR)2 and TLR4 in human peripheral blood granulocytes: a critical role for monocytes in leukocyte lipopolysaccharide responses. J Immunol 168 9 (2002) 4701-4710
36. Kurt-Jones E.A., Mandell L., Whitney C., et al. Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils. Blood 100 5 (2002) 1860-1868